Diabetes mellitus is an independent risk factor for cardiovascular disease

Terapevticheskii Arkhiv

Volumn 84, Issue 8, 2012, Pages 91-94

  Ametov, A S ^a   Kulidzhanyan, N K ^a  

^a Ministry of Health and Social Development of Russia   (Russian Federation)

Author keywords

Cardiovascular diseases; Incretin drugs; Metformin; Type 2 diabetes mellitus

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; RISK;

EID: 84867954973     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Shaw J.E., Sicree R.A., Zimmet P.Z. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87:1:4-14.
2. Niskanen L., Turpeinrn A., Penttila I., Uusitupa M.I. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 1998; 21: 11: 1861-1869. (Pubitemid 28478284)
3. Malmberg K., Rydin L., Wedel H., et al. for the DIGAMI 2 Investigators Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650-661. (Pubitemid 40516876)
4. Stratton J.M., Adler A.L, Neil A. W., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective, observational study. Br Mtd J 2000 321; 405-412.
5. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444. (Pubitemid 23046633)
6. Yusuf S., Hawken S., Ounpuu S., et al. for the INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 9438:937-952. (Pubitemid 39208455)
7. Cefalu W. T. Glycemic targets and cardiovascular disease. N Engl J Med 2008; 358: 2633-2635. doi: 10.1056/NEJMe0803831. (Pubitemid 351831366)
8. Kelly T., Bazzano L., Fonseca V., et al. Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151:1-13.
9. Ray K.K., Seshasai S.R., Wijesuriya S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 9677: 1765-1772. doi: 10.1016/SO 140-6736(09)60697-8.
10. American Diabetes Association; National Hert, Lung and Blood Institute; Juvenile Diabetes Foundation International; National Institute of Diabetes and Digestive and Kidney Disease; American Heart Association. Diabetes Mellitus: a major risk factor for cardiovascular disease. Circulation 1999; 100:1132-1133.
11. Wu M.S., Johnston P., Sheu W.H.H., et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13:1-8. (Pubitemid 20024723)
12. Despres J.P. Potential contribution of metformin to the management of cardio- vascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diab Metabol 2003; 29:6553-6561.
13. CharlesA., Vague P., MorangeP., et al. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects. The BIGPROL Study. Diabetes Care 1998; 11:1967-1972. (Pubitemid 28478302)
14. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:9131: 837-853.
15. Chan N. Improved endothelial function with metformin in type 2 diabetes mellitus. JAM Coll Cardial 2001; 38: 2131-2132.
16. Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007; 30:1335-1343. (Pubitemid 46871135)
17. Nauck M.A. Unraveling the science ofincretin biology. Am J Med 2009; 122: S3-S10.
18. Atnori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194-206. (Pubitemid 47057766)
19. Brixner D.I., McAdam-Marx C, YeX., et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab 2009; 11:12:1122-1130.
20. Apovian CM., Bergenstal R.M., Cuddihy R.M., et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010; 123:5:468.e9-17.
21. Sullivan S.D., Alfonso-Cristancho R., Conner C., et al. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide of rosiglitazone. Cardiovasc Diabetol 2009; 26:8:12.
22. Courreges J.P., Vilsboll T., Zdravkovic M. et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabetes Med 2008; 25:9: 1129-1131.
23. Bunck M.C., Diamant M., Eliasson B., et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010; 33:8: 1734-1737.
24. Read PA., Khan F.Z., Heck P.M., et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010;3:2:195-201.
25. DCCT/EDIC Epidemiology of Diabetes Interventions and Complications Research randomized Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes. N Engl J Med 2003; 348: 2294-2303.
26. Tzoulaki I., Molokhia M., Curcin V., et al. Risk of cardiovascular disease and all cuase mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: study using UK general practice research database. Br Mrd J 2009; 339: b4731.
27. Evans J.M., Ogston S.A., Emslie-Smith A., et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas metformin. Diabetologia 2006; 49:930-936.
28. Johnson J.A., Majundar S.R., Simpson S.H., et al. Decreased mortality associated with the use of metformin compared with sulfonylurea in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248. (Pubitemid 41071035)
29. Wolf R., Frederich R., Ftedorek F., et al. Evaluation of CV risk in saxagliptin clinical trials [abstract no.8-LB plus poster]. 69th Annual Scientific Sessions of the American Diabetes Association. New Orleans 2009.